U.S. Food and Drug Administration Approval: Rituximab in Combination with Fludarabine and Cyclophosphamide for the Treatment of Patients with Chronic Lymphocytic Leukemia

door Casak, Sandra J., Lemery, Steven J., Shen, Yuan Li, Rothmann, Mark D., Khandelwal, Aakanksha, Zhao, Hong, Davis, Gina, Jarral, Vaishali, Keegan, Patricia, Pazdur, Richard
Gepubliceerd in 2011

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

door Pelosof, Lorraine, Lemery, Steven, Casak, Sandra, Jiang, Xiaoping, Rodriguez, Lisa, Pierre, Vadryn, Bi, Youwei, Liu, Jiang, Zirkelbach, Jeanne Fourie, Patel, Anuja, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Gepubliceerd in Oncologist (2018)

Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine...

door Pelosof, Lorraine, Saung, May Tun, Donoghue, Martha, Casak, Sandra, Mushti, Sirisha, Cheng, Joyce, Jiang, Xiling, Liu, Jiang, Zhao, Hong, Khazraee, Maryam, Goldberg, Kirsten B., Theoret, Marc, Lemery, Steven, Pazdur, Richard, Fashoyin‐Aje, Lola
Gepubliceerd in Oncologist (2021)